immunogenicity 

75641
单词释义
n.免疫原性;致免疫性;致免疫力
单词例句
The vaccine demonstrated excellent immunogenicity, eliciting a strong immune response in all participants.
该疫苗展现出极高的免疫原性,使所有参与者都产生了强烈的免疫反应。
The new cancer vaccine has shown promising immunogenicity, triggering a robust T-cell response.
这种新的癌症疫苗显示出有希望的免疫原性,能够激发强烈的T细胞反应。
The food additive was found to be non-immunogenic, causing no adverse reactions in the test subjects.
这种食品添加剂被证实不具有免疫原性,没有在受试者中引发任何不良反应。
The protein from the virus is known to be highly immunogenic, leading to a protective immunity.
病毒的蛋白质被认为具有高度免疫原性,能产生保护性的免疫力。
The experimental drug demonstrated low immunogenicity, making it suitable for patients with allergies.
实验药物显示出低免疫原性,适合对某些成分过敏的患者使用。
The vaccine's efficacy relies heavily on its ability to induce immunogenicity, or else it won't protect against the disease.
疫苗的有效性很大程度上取决于其诱发免疫原性的能力,否则无法预防疾病。
The child's immune system responded positively to the new vaccine, indicating good immunogenicity.
孩子的免疫系统对新疫苗作出了积极反应,说明其免疫原性良好。
Researchers are exploring ways to enhance the immunogenicity of cancer vaccines to improve patient outcomes.
研究人员正在研究如何提高癌症疫苗的免疫原性,以期改善患者的治疗效果。
The study showed that repeated exposure to the antigen increased its immunogenicity over time.
研究显示,反复接触抗原会随着时间推移增加其免疫原性。
The company is focusing on developing new adjuvants to improve the immunogenicity of their vaccines.
公司正致力于研发新型辅助剂,以增强其疫苗的免疫原性。
The clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3-year-old and above.
该临床试验旨在评估四价流感疫苗在3岁及以上人群中的免疫原性和安全性。
Chinese vaccine producer Sinovac Biotech officially kicked off a clinical trial in Hong Kong on Monday to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine which will be used as a booster shot in healthy adults.
中国疫苗生产商科兴生物周一在香港正式启动临床试验,以评估其奥密克戎特异性新冠肺炎灭活疫苗的安全性和免疫原性,该疫苗将用于健康成年人的加强针。
Both in vitro and in vivo experiments have demonstrated the effectiveness of LinearDesign in improving the stability and immunogenicity of spike protein-encoding mRNA, the company claimed.
该公司声称,体外和体内实验都证明了LinearDesign在提高编码刺突蛋白mRNA的稳定性和免疫原性方面的有效性。
The study is a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate.
这项研究是一项全球性的关键性2/3期临床试验,旨在评估SCB-2019(CpG 1018/Alum),即Clover公司COVID-19疫苗候选产品的有效性、安全性和免疫原性。
Clover is currently advancing SPECTRA, a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of SCB-2019 (CpG 1018/Alum), and expects interim data for vaccine efficacy around the middle of 2021.
Clover正在积极推进SPECTRA,这是一项全球性的关键性2/3期临床试验,旨在评估SCB-2019(CpG 1018/Alum)疫苗的有效性、安全性和免疫原性。公司预计在2021年中左右获得中期的疫苗效力数据。
Chinese clinical-stage biotech Clover Biopharmaceuticals and Nasdaq-listed biopharmaceutical company Dynavax Technologies Corporation announced on Wednesday the first participants have been dosed in Clover's global Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum.
中国临床阶段生物技术公司三叶草生物制药和纳斯达克上市生物制药公司Dynavax Technologies Corporation周三宣布,三叶草全球II/III期临床试验已开始给药,该试验旨在评估其基于蛋白质的S-Trimer新冠疫苗候选产品与Dynavax的CpG 1018加佐剂联合使用在疗效、安全性和免疫原性方面的表现。
The online recruitment of volunteers will commence with the recruitment of 960 healthy participants, aged between 18 and 85, to assess the safety and immunogenicity of the vaccine candidate and to support future biologic license applications in China.
在线志愿者招募将首先招募960名18至85岁的健康参与者,以评估疫苗候选人的安全性和免疫原性,并支持未来在中国的生物制品许可申请。
未经许可,严禁转发。QQ交流群:688169419
0
近30天助记贡献排行榜
网友新增怎么记信息
最新查询次数奖励榜
0